A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin

British Journal of Cancer

Volumn 90, Issue 6, 2004, Pages 1285-1292

  Tang, H J ^a   Qian, D ^a   Sondak, V K ^a   Stachura, S ^a   Lin, J ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b CCGC 4215 ^*  (United States)

Author keywords

Apoptosis; Cisplatin; Doxorubicin; Mdm2; p53; Sarcoma cell lines

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; DOXORUBICIN; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; FIBROSARCOMA; GENE MUTATION; GENE TRANSFER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SARCOMA; SARCOMA CELL; WILD TYPE;

ADENOVIRIDAE; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GENES, P53; GENETIC VECTORS; HUMANS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SARCOMA; TUMOR CELLS, CULTURED; ZINC FINGERS;

EID: 1942469420     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601653     Document Type: Article

References (73)

1. Achanta G, Pelicano H, Feng L, Plunkett W, Huang P (2001) Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res 61: 8723-8729
2. Appella E, Anderson C (2000) Signaling to p53: breaking the posttranslational modification code. Pathol Biol 48: 227-245
3. Beaudry G, Bertelsen A, Sherman M (1996) Therapeutic targeting of the p53 tumor suppressor gene. Curr Opin Biotechnol 7: 592-600
4. Blagosklonny M, El-Deiry W (1998) Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 75: 933-940
5. Chan H, Thorner P, Haddad G, Ling V (1990) Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8: 689-704
6. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD (1999) Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 9613777-82: 13777-13782
7. Chehab N, Malikzay A, Appel M, Halazonetis T (2000) Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53. Genes Dev 14: 278-288
8. Chen J, Lin J, Levine A (1995) Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med 1: 142-152
9. Chen J, Wu X, Lin J, Levine A (1996) mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16: 2445-2452
10. Cocker H, Hobbs S, Tiffin N, Pritchard-Jones K, Pinkerton C, Kelland L (2001) High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br J Cancer 85: 1746-1752
11. Donehower LA, Bradley A (1993) The tumor suppressor p53. Biochim Biophys 1155: 181-205
12. Evdokiou A, Cowled PA (1998) Tumor-suppressive activity of the growth arrest-specific gene GAS1 in human tumor cell lines. Int J Cancer 75: 568-577
13. Gao C, Nakajima T, Taya Y, Tsuchida N (1999) Activation of p53 in MDM2-overexpressing cells through phosphorylation. Biochem Biophys Res Commun 2: 860-864
14. Hann B, Balmain A (2003) Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-mutants. J Virol 77: 11588-11595
15. Haupt Y, Maya R, Kazaz A, Oren M (1997a) mdm2 promotes the rapid degradation of p53. Nature 387: 296-299
16. Haupt Y, Rowan S, Shaulian E, Kazaz A, Vousden K, Oren M (1997b) p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms. Leukemia 13: 337-339
17. Hermeking H, Eick D (1994) Mediation of c-Myc-induced apoptosis by p53. Science 265: 2091-2093
18. Higashimoto Y, Saito S, Tong XH, Hong A, Sakaguchi K, Appella E, Anderson C (2000) Human p53 is phosphorylated on serines 6 and 9 in response to DNA damage-inducing agents. J Biol Chem 275: 23199-23203
19. Hiyama H, Reeves S (1999) Role for cyclin D1 in UVC-induced and p53-mediated apoptosis. Cell Death Differ 6: 565-569
20. Hoffman J, Schmidt-Peter P, Hansch W, Naundorf H, Bunge A, Becker M, Fichtner I (1999) Anticancer sensitivity and expression of multidrug resistance markers in early passage human sarcomas. Clin Cancer Res 5: 2198-2204
21. Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27
22. Jiminez R, Zalupski M, Frank J, Du W, Ryan J, Lucas D (1999) Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer 86: 976-981
23. Joensuu H, Roberts P, Sarlomo-Rikala M, Andersson L, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri G (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052-1056
24. Keleti J, Quezado M, Abaza M, Raffeld M, Tsokos M (1996) The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol 149: 143-151
25. Knudson C, Tung K, Tourtellotte W, Brown G, Korsmeyer S (1995) Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270: 96-99
26. Ko S, Gotoh A, Thalmann G, Zhau H, Johnston D, Zhang W, Kao C, Chung L (1996) Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum Gene Ther 7: 1683-1691
27. Kondo S, Barnett G, Hara H, Morimura T, Takeuchi J (1995) MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10: 2001-2006
28. Kondo S, Kondo Y, Hara H, Kaakaji R, Peterson J, Morimura T, Takeuchi J, Barnett G (1996) Mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. Br J Cancer 74: 1263-1268
29. Kubbutat M, Jones S, Vousden K (1997) Regulation of p53 stability by mdm2. Nature 387: 299-303
30. Kubbutat M, Ludwig R, Ashcroft M, Vousden K (1998) Regulation of mdm2-directed degradation by the C terminus of p53. Mol Cell Biol 18: 5690-5698
31. Landers J, Cassel S, George D (1997) Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 57: 3562-3568
32. Leach F, Tokino T, Meltzer P, Burrell M, Oliner J, Smith S, Hill D, Sidransky D, Kinzler K, Vogelstein B (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231-2234
33. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453-456
34. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E (1998) Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 273: 23419-23425
35. Li W, Takahashi N, Jhanwar S, Cordon-Cardo C, Elisseyeff Y, Jimeno J, Faircloth G, Bertino J (2001) Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 7: 2908-2911
36. Lin J, Chen J, Elenbaas B, Levine AJ (1994) Several hydrophobic amino acids in the p53 N-terminal domain are required for transcriptional activation, binding to mdm-2 and the Adenovirus 5 E1B 55kd protein. Genes Dev. 8: 1235-1246
37. Lin J, Jin X, Page C, Sondak VK, Jiang G, Reynolds KR (2000) A modified p53 overcomes mdm2-mediated oncogenic transformation. Cancer Res 60: 5895-5901
38. Lin J, Reichner C, Wu X, Levine AJ (1996) Analysis of wild-type and mutant P21WAF-1 gene activities. Mol Cell Biol 16: 1786-1793
39. Lowe S, Bodis S, McClatchey A, Remington L, Ruley H, Fisher D, Housman D, Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810
40. Lowe S, Ruley H, Jacks T, Housman D (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967
41. Malcomson R, Oren M, Wyllie A, Harrison D (1995) p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Br J Cancer 72: 952-957
42. Masuda H, Ozols R, Lai G, Fojo A, Rothenberg M, Hamilton T (1998) Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 48: 5713-5716
43. McCurrach M, Connor T, Knudson C, Korsmeyer S, Lowe S (1997) bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 94: 2345-2349
44. Medrano EE, Im S, Yang F, Abdel-Malek ZA (1995) Ultraviolet B light induces G1 arrest in human melanocytes by prolonged inhibition of retinoblastoma protein phosphorylation associated with long-term expression of the p21Waf-1/SDI-1/Cip-1 protein. Cancer Res 55: 4047-4052
45. Meng R, Shih H, Prabhu N, George D, el-Deiry W (1998) Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin Cancer Res 4: 251-259
46. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll U (2003) p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11: 577-590
47. Miyashita T, Reed J (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299
48. Momand J, Jung D, Wilczynski S, Niland J (1998) The MDM2 gene amplification database. Nucleic Acids Res 26: 3453-3459
49. Momand J, Zambetti G, Olson D, George D, Levine A (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245
50. Nakayama T, Toguchida J, Wadayama B, Kanoe H, Kotoura Y, Sasaki M (1995) MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer 64: 342-346
51. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y (2000) p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862
52. Oliner J, Kinzler K, Meltzer P, George D, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83
53. Oliner J, Pietenpol J, Thiagalingam S, Gyuris J, Kinzler K, Vogelstein B (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860
54. Prives C, Hall P (1999) The p53 pathway. J Pathol 187: 112-126
55. Sakaguchi K, Herrera J, Saito S, Miki T, Bustin M, Vassilev A, Anderson C, Appella E (1998) DNA damage activates p53 through a phosphorylation - acetylation cascade. Genes Dev 15: 2831-2841
56. Shieh S, Ikeda M, Taya Y, Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334
57. Shono T, Tofilon PJ, Schaefer TS, Parikh D, Liu TJ, Lang FF (2002) Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res 62: 1069-1076
58. Siliciano J, Canman C, Taya Y, Sakaguchi K, Appella E, Kastan M (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11: 3471-3481
59. Sondak V, Chang A (2001) Clinical evaluation and treatment of soft tissue tumors. In: Weiss SW, Goldblum JR (eds) Enzinger and Weiss's Soft Tissue Tumors, 4th edn, pp. 21-44. Missouri: Mosby, St Louis
60. Stine K, Saylors R, Saccente S, Becton DL (2003) Long-term survival in osteosarcoma patients following retinoblastoma using doxorubicin, cisplatin, and methotrexate. Med Pediatr Oncol 41: 77-78
61. Suzuki A, Toi M, Yamamoto Y, Saji S, Muta M, Tominaga T (1998) Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res 89: 221-227
62. Tibbetts R, Brumbaugh K, Williams J, Sarkaria J, Cliby W, Shieh S, Taya Y, Prives C, Abraham R (1999) A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 15: 152-157
63. Vikhanskaya F, Clerico L, Valenti M, Stanzione M, Broggini M, Parodi S, Russo P (1997) Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53. Int J Cancer 72: 155-159
64. Vogelstein B, Kinzler KW (1992) p53 function and dysfunction. 70: 523-526
65. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310
66. Wagner A, Kokontis J, Hay N (1994) Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev 8: 2817-2830
67. Weinstein J, Myers T, O'Connor P, Friend S, Fornace AJ, Kohn K, Fojo T, Bates S, Rubinstein L, Anderson N, Buolamwini J, van Osdol W, Monks A, Scudiero D, Sausville E, Zaharevitz D, Bunow B, Viswanadhan V, Johnson G, Wittes R, Paull K (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343-349
68. Yaginuma Y, Westphal H (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52: 4196-4199
69. Yan Y, Shay J, Wright W, Mumby M (1997) Inhibition of protein phosphatase activity induces p53-dependent apoptosis in the absence of p53 transactivation. J Biol Chem 2772: 15220-15226
70. Yang C, Cirielli C, Capogrossi M, Passaniti A (1995) Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 55: 4210-4213
71. Yin C, Knudson C, Korsmeyer S, Van DT (1997) Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385: 637-640
72. Zhan M, Yu D, Lang A, Li L, Pollock R (2001) Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer 92: 1556-1566
73. Zhang W, Alemany R, Wang J, Koch P, Ordonez N, Roth J (1995) Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gene Ther 6: 155-164